Insider Selling: Natera, Inc. (NASDAQ:NTRA) CFO Sells 2,562 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 2,562 shares of the business’s stock in a transaction dated Monday, March 31st. The shares were sold at an average price of $138.41, for a total value of $354,606.42. Following the completion of the sale, the chief financial officer now directly owns 75,557 shares of the company’s stock, valued at approximately $10,457,844.37. This trade represents a 3.28 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, March 17th, Michael Burkes Brophy sold 792 shares of Natera stock. The stock was sold at an average price of $146.04, for a total value of $115,663.68.
• On Monday, February 3rd, Michael Burkes Brophy sold 43,502 shares of Natera stock. The shares were sold at an average price of $176.88, for a total value of $7,694,633.76.
• On Wednesday, January 29th, Michael Burkes Brophy sold 4,335 shares of Natera stock. The stock was sold at an average price of $165.87, for a total transaction of $719,046.45.
• On Friday, January 31st, Michael Burkes Brophy sold 1,886 shares of Natera stock. The shares were sold at an average price of $176.60, for a total transaction of $333,067.60.
• On Monday, January 27th, Michael Burkes Brophy sold 1,442 shares of Natera stock. The shares were sold at an average price of $161.87, for a total transaction of $233,416.54.
• On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The stock was sold at an average price of $171.98, for a total transaction of $162,693.08.
• On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The shares were sold at an average price of $164.97, for a total value of $4,277,837.07.

Natera Stock Down 0.5 %

Shares of NASDAQ:NTRA traded down $0.76 on Tuesday, hitting $140.65. 1,583,711 shares of the company traded hands, compared to its average volume of 1,370,306. The stock has a 50 day simple moving average of $158.72 and a 200-day simple moving average of $151.35. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The company has a market cap of $19.01 billion, a PE ratio of -79.91 and a beta of 1.80. Natera, Inc. has a 52 week low of $83.13 and a 52 week high of $183.00.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. The business had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. As a group, research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Institutional Trading of Natera

A number of institutional investors and hedge funds have recently modified their holdings of NTRA. Daiwa Securities Group Inc. bought a new stake in shares of Natera in the third quarter worth approximately $232,000. The Manufacturers Life Insurance Company raised its stake in Natera by 87.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 67,906 shares of the medical research company’s stock valued at $8,621,000 after buying an additional 31,649 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Natera by 5.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,339 shares of the medical research company’s stock valued at $3,344,000 after buying an additional 1,263 shares during the period. Captrust Financial Advisors lifted its holdings in shares of Natera by 108.7% during the 3rd quarter. Captrust Financial Advisors now owns 5,689 shares of the medical research company’s stock valued at $722,000 after buying an additional 2,963 shares during the period. Finally, Paloma Partners Management Co bought a new stake in shares of Natera in the third quarter worth $238,000. Institutional investors own 99.90% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Sanford C. Bernstein lifted their price objective on Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, January 10th. The Goldman Sachs Group upped their price objective on shares of Natera from $160.00 to $190.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. Robert W. Baird lifted their target price on shares of Natera from $183.00 to $188.00 and gave the company an “outperform” rating in a research note on Friday, February 28th. BTIG Research reissued a “buy” rating on shares of Natera in a research note on Friday, February 28th. Finally, StockNews.com raised Natera from a “sell” rating to a “hold” rating in a research report on Wednesday, March 19th. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and an average target price of $178.12.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.